Dulaglutide
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Company n/r · Phase 3 · Completed · Enrollment 159
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| obese , non diabetic ,recieve dulaglutide | n/r | n/r | n/r | n/r |
| obese , non diabetic ,receive SEMAGLUTIDE | n/r | n/r | n/r | n/r |
| obese , non diabetic ,receive TIRAZEPETIDE | n/r | n/r | n/r | n/r |
| obese , diabetic ,recieve dulaglutide | n/r | n/r | n/r | n/r |
| obese , diabetic ,receive SEMAGLUTIDE | n/r | n/r | n/r | n/r |
| obese , diabetic ,receive TIRAZEPETIDE | n/r | n/r | n/r | n/r |
Not shown
- obese , non diabetic ,recieve dulaglutide: endpoint not reported
- obese , non diabetic ,receive SEMAGLUTIDE: endpoint not reported
- obese , non diabetic ,receive TIRAZEPETIDE: endpoint not reported
- obese , diabetic ,recieve dulaglutide: endpoint not reported
- obese , diabetic ,receive SEMAGLUTIDE: endpoint not reported
- obese , diabetic ,receive TIRAZEPETIDE: endpoint not reported